US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Articles published by Apollomics Inc.

News headline image
Apollomics Announces $10 Million Private Placement Transaction
From Apollomics Inc.
Via GlobeNewswire
Tickers APLM APLMW
News headline image
Apollomics Regains Full Compliance with Nasdaq Listing Requirements
From Apollomics Inc.
Via GlobeNewswire
Tickers APLM APLMW
News headline image
Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia
From Apollomics Inc.
Via GlobeNewswire
Tickers APLM APLMW
News headline image
Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress
From Apollomics Inc.
Via GlobeNewswire
Tickers APLM APLMW
News headline image
Apollomics Inc. Announces $2.0 Million Bridge Financing
From Apollomics Inc.
Via GlobeNewswire
Tickers APLM APLMW
News headline image
Apollomics Reports First Half 2025 Financial Results
From Apollomics Inc.
Via GlobeNewswire
Tickers APLM APLMW
News headline image
Apollomics Announces Settlement of Cayman Litigation
From Apollomics Inc.
Via GlobeNewswire
Tickers APLM APLMW
News headline image
Apollomics Announces Changes to its Board of Directors and Composition of Committees
From Apollomics Inc.
Via GlobeNewswire
Tickers APLM APLMW
News headline image
Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation
From Apollomics Inc.
Via GlobeNewswire
Tickers APLM APLMW
News headline image
Apollomics, Inc. Company Operational Continuity Update
From Apollomics Inc.
Via GlobeNewswire
Tickers APLM APLMW
News headline image
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress
From Apollomics Inc.
Via GlobeNewswire
Tickers APLM APLMW
News headline image
Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib
From Apollomics Inc.
Via GlobeNewswire
Tickers APLM APLMW
News headline image
Apollomics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
From Apollomics Inc.
Via GlobeNewswire
Tickers APLM APLMW
News headline image
Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split
From Apollomics Inc.
Via GlobeNewswire
Tickers APLM APLMW
News headline image
Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024
From Apollomics Inc.
Via GlobeNewswire
Tickers APLM APLMW
News headline image
Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Apollomics Inc.
Via GlobeNewswire
Tickers APLM APLMW
News headline image
Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress
From Apollomics Inc.
Via GlobeNewswire
Tickers APLM APLMW
News headline image
Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial
From Apollomics Inc.
Via GlobeNewswire
Tickers APLM APLMW
News headline image
Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference
From Apollomics Inc.
Via GlobeNewswire
Tickers APLM APLMW
News headline image
Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement
From Apollomics Inc.
Via GlobeNewswire
Tickers APLM APLMW
News headline image
Apollomics Announces Updated Strategic Focus and Leadership Team Changes
From Apollomics Inc.
Via GlobeNewswire
Tickers APLM APLMW
News headline image
Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Apollomics Inc.
Via GlobeNewswire
Tickers APLM APLMW
News headline image
Apollomics Announces Presentation at the 2024 BIO International Convention
From Apollomics Inc.
Via GlobeNewswire
Tickers APLM APLMW
News headline image
Apollomics Announces Private Placement Financing and Addition to Board of Directors
From Apollomics Inc.
Via GlobeNewswire
Tickers APLM APLMW
News headline image
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene
From Apollomics Inc.
Via GlobeNewswire
Tickers APLM APLMW
News headline image
Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
From Apollomics Inc.
Via GlobeNewswire
Tickers APLM APLMW
News headline image
Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
From Apollomics Inc.
Via GlobeNewswire
Tickers APLM APLMW
News headline image
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
From Apollomics Inc.
Via GlobeNewswire
Tickers APLM APLMW
News headline image
Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024
From Apollomics Inc.
Via GlobeNewswire
Tickers APLM APLMW
News headline image
Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer
From Apollomics Inc.
Via GlobeNewswire
Tickers APLM APLMW